Does first‐line treatment have prognostic impact for unresectable HCC ?—Atezolizumab plus bevacizumab versus lenvatinib
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Does first‐line treatment have prognostic impact for unresectable
HCC
?—Atezolizumab plus bevacizumab versus lenvatinib
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-06-04
DOI
10.1002/cam4.4854
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
- (2021) Masatoshi Kudo et al. JOURNAL OF GASTROENTEROLOGY
- Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis
- (2021) Toshifumi Tada et al. ONCOLOGY
- Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
- (2021) Keisuke Koroki et al. Liver Cancer
- Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
- (2021) Atsushi Hiraoka et al. Scientific Reports
- Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
- (2021) Atsushi Hiraoka et al. HEPATOLOGY RESEARCH
- Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
- (2021) Yuka Hayakawa et al. INVESTIGATIONAL NEW DRUGS
- Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma
- (2021) Kazufumi Kobayashi et al. Liver Cancer
- Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
- (2020) Josep M. Llovet et al. HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome
- (2020) Akira Fuchigami et al. PLoS One
- Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
- (2020) Yuwa Ando et al. ONCOLOGY
- Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
- (2020) Tomoko Aoki et al. Cancers
- The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study
- (2020) Takeshi Hatanaka et al. ONCOLOGY
- Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
- (2019) Atsushi Hiraoka et al. Cancer Medicine
- Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
- (2019) Atsushi Hiraoka et al. ONCOLOGY
- Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
- (2019) Masatoshi Kudo et al. Cancers
- Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
- (2019) Atsushi Hiraoka et al. ONCOLOGY
- Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib
- (2019) Atsushi Hiraoka et al. Liver Cancer
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
- (2017) Atsushi Hiraoka et al. Liver Cancer
- Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
- (2016) Atsushi Hiraoka et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
- (2015) Takeshi Terashima et al. HEPATOLOGY RESEARCH
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
- (2015) JOURNAL OF HEPATOLOGY
- Epidemiology of Hepatocellular Carcinoma
- (2013) Sahil Mittal et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
- (2012) Y Kanda BONE MARROW TRANSPLANTATION
- Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
- (2011) Katsuhiro Sano et al. RADIOLOGY
- Intraindividual Comparison of Gadoxetate Disodium–enhanced MR Imaging and 64-Section Multidetector CT in the Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
- (2010) Michele Di Martino et al. RADIOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More